Delving into the Latest Updates on Cheng Du Sheng Nuo Biotec Co., Ltd. with Synapse

Overview

Tags

Respiratory Diseases

Infectious Diseases

Prophylactic vaccine

mRNA vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	2
Immune System Diseases	1

Top 5 Drug Type	Count

Synthetic peptide	3
Prophylactic vaccine	1
mRNA vaccine	1

Top 5 Target	Count

SARS-CoV-2 S protein	1
PTH1R(Parathyroid hormone receptor)	1
Hsp60(heat shock protein family D (Hsp60) member 1)	1

主要目的：以国内上市的 AstraZeneca AB 的艾塞那肽注射液作为参比制剂，评价成都圣诺生物制药有限公司生产的艾塞那肽注射液与参比制剂的生物等效性；次要目的：评价成都圣诺生物制药有限公司生产的艾塞那肽注射液的安全性，以及抗药抗体对艾塞那肽药代动力学的影响。

[Translation]

Primary objective: To evaluate the bioequivalence of exenatide injection produced by Chengdu Shengnuo Biopharmaceutical Co., Ltd. with the reference preparation, using AstraZeneca AB's exenatide injection, which is marketed in China, as the reference preparation; Secondary objective: To evaluate the safety of exenatide injection produced by Chengdu Shengnuo Biopharmaceutical Co., Ltd. and the effect of anti-drug antibodies on the pharmacokinetics of exenatide.

Start Date03 Apr 2023

Sponsor / Collaborator

Chengdu Shengnuo Biotechnology Co., Ltd.

CTR20211463

/ CompletedNot Applicable

利拉鲁肽注射液在健康受试者中单次给药、随机、开放、两周期、两交叉、空腹状态下生物等效性试验

[Translation] A single-dose, randomized, open-label, two-period, two-crossover, fasting bioequivalence study of liraglutide injection in healthy subjects

以成都圣诺生物制药有限公司研制的利拉鲁肽注射液（规格：3mL:18mg）为受试制剂（T），诺和诺德（中国）制药有限公司生产的利拉鲁肽注射液（商品名：诺和力 ®，规格：3mL:18mg）为参比制剂（R），研究受试制剂和参比制剂在健康受试者空腹状态下单剂量给药时的药代动力学参数，初步进行两种制剂的人体生物等效性评价。

[Translation]

Liraglutide injection (specification: 3mL:18mg) developed by Chengdu Shengnuo Biopharmaceutical Co., Ltd. was used as the test preparation (T), and liraglutide injection (trade name: Novoligy®, specification: 3mL:18mg) produced by Novo Nordisk (China) Pharmaceuticals Co., Ltd. was used as the reference preparation (R). The pharmacokinetic parameters of the test preparation and the reference preparation were studied when administered as a single dose in healthy volunteers under fasting state, and the human bioequivalence of the two preparations was preliminarily evaluated.

Start Date29 Jun 2021

Sponsor / Collaborator

Chengdu Shengnuo Biotechnology Co., Ltd.

CTR20210822

/ CompletedNot Applicable

艾塞那肽注射液随机、开放、两制剂、两序列、两周期、交叉单剂量人体生物等效性临床研究

[Translation] A randomized, open-label, two-formulation, two-sequence, two-period, crossover single-dose clinical study on bioequivalence of exenatide injection in humans

主要目的：以国内上市的 AstraZeneca AB 的艾塞那肽注射液作为参比制剂，评价成都圣诺生物制药有限公司生产的艾塞那肽注射液与参比制剂的生物等效性；次要目的：评价成都圣诺生物制药有限公司生产的艾塞那肽注射液的安全性，以及抗药抗体对艾塞那肽药代动力学的影响。

[Translation]

Primary objective: To evaluate the bioequivalence of exenatide injection produced by Chengdu Shengnuo Biopharmaceutical Co., Ltd. with the reference preparation, using the domestically marketed exenatide injection of AstraZeneca AB as the reference preparation; Secondary objective: To evaluate the safety of exenatide injection produced by Chengdu Shengnuo Biopharmaceutical Co., Ltd. and the effect of anti-drug antibodies on the pharmacokinetics of exenatide.

Start Date12 Apr 2021

Sponsor / Collaborator

Chengdu Shengnuo Biotechnology Co., Ltd.

100 Clinical Results associated with Cheng Du Sheng Nuo Biotec Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Cheng Du Sheng Nuo Biotec Co., Ltd.

Login to view more data

100 Deals associated with Cheng Du Sheng Nuo Biotec Co., Ltd.

Login to view more data

100 Translational Medicine associated with Cheng Du Sheng Nuo Biotec Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 May 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

IND Application

Phase 1

1

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CIGB-814 ( Hsp60 )	Rheumatoid Arthritis More	Phase 1
RIM730 ( SARS-CoV-2 S protein )	COVID-19 More	Preclinical
AOD53724	Coronavirus Infections More	Preclinical
LLP2A alendronate	Osteonecrosis More	Pending
Nesiritide Recombinant ( NPRA )	Dyspnea More	Pending